Literature DB >> 20191199

Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide in patients with pulmonary tuberculosis.

Mônica C Façanha1, Argina M B Gondim, Valéria G F Pinheiro, Elizabeth C Barroso, Charles A Peloquin, Richard L Guerrant, Aldo A M Lima.   

Abstract

Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide were studied in healthy controls and patients with active pulmonary tuberculosis. A case-control study of 29 controls and 30 cases attending at the Health Center, July, 2004 to December, 2005 was conducted. The body mass index was significantly reduced in cases compared to controls (p < 0.001). The intestinal paracellular transport of lactulose was significantly (p = 0.019) reduced in cases compared to controls. The transcellular transport of mannitol and the lactulose:mannitol ratio were not significantly (p = 0.0698) reduced in cases compared to controls. Low serum concentrations of rifampin, isoniazid and pyrazinamide were observed in 81% (48/59), 92% (54/59) and 28% (12/59), respectively, in all individuals. The results demonstrated a marked decrease on intestinal paracellular transport in patients with active pulmonary tuberculosis and reduced serum concentrations of rifampin and isoniazid in both groups.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20191199     DOI: 10.1590/s1413-86702009000300011

Source DB:  PubMed          Journal:  Braz J Infect Dis        ISSN: 1413-8670            Impact factor:   1.949


  6 in total

1.  Markers of gut dysfunction do not explain low rifampicin bioavailability in HIV-associated TB.

Authors:  Christopher Vinnard; Shruthi Ravimohan; Neo Tamuhla; Jotam Pasipanodya; Shashikant Srivastava; Chawangwa Modongo; Nicola M Zetola; Drew Weissman; Tawanda Gumbo; Gregory P Bisson
Journal:  J Antimicrob Chemother       Date:  2017-07-01       Impact factor: 5.790

2.  Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV.

Authors:  Kidola Jeremiah; Paolo Denti; Emmanuel Chigutsa; Daniel Faurholt-Jepsen; George PrayGod; Nyagosya Range; Sandra Castel; Lubbe Wiesner; Christian Munch Hagen; Michael Christiansen; John Changalucha; Helen McIlleron; Henrik Friis; Aase Bengaard Andersen
Journal:  Antimicrob Agents Chemother       Date:  2014-04-07       Impact factor: 5.191

3.  A Pilot Study of Immune Activation and Rifampin Absorption in HIV-Infected Patients without Tuberculosis Infection: A Short Report.

Authors:  Christopher Vinnard; Isabel Manley; Brittney Scott; Mariana Bernui; Joella Adams; Sheryl Varghese; Isaac Zentner; Michele A Kutzler
Journal:  Tuberc Res Treat       Date:  2017-12-21

Review 4.  Microbiome-immune interactions in tuberculosis.

Authors:  Giorgia Mori; Mark Morrison; Antje Blumenthal
Journal:  PLoS Pathog       Date:  2021-04-15       Impact factor: 6.823

5.  Effect of Rifabutin in Dolutegravir Dosing: A Case Series.

Authors:  Maria A Mendoza; Mohammad H Alshaer; Giovanni Roldan; Jose Guillermo Castro; David Ashkin; Charles A Peloquin; Catherine V Boulanger
Journal:  J Int Assoc Provid AIDS Care       Date:  2022 Jan-Dec

Review 6.  Current research toward optimizing dosing of first-line antituberculosis treatment.

Authors:  Helen McIlleron; Maxwell T Chirehwa
Journal:  Expert Rev Anti Infect Ther       Date:  2018-12-12       Impact factor: 5.091

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.